Talis Biomedical (NASDAQ:TLIS) Trading Down 1.5% – Time to Sell?

Talis Biomedical Co. (NASDAQ:TLIS) shares traded down 1.5% during mid-day trading on Thursday . The company traded as low as $1.64 and last traded at $1.70. 1,506 shares changed hands during mid-day trading, a decline of 90% from the average session volume of 14,400 shares. The stock had previously closed at $1.72.

Talis Biomedical Stock Performance

The stock’s fifty day moving average price is $3.02 and its 200-day moving average price is $6.78. The firm has a market cap of $3.12 million, a PE ratio of -0.05 and a beta of 1.57.

Talis Biomedical (NASDAQ:TLIS) last issued its quarterly earnings data on Monday, August 19th. The company reported ($4.86) EPS for the quarter. Talis Biomedical had a negative net margin of 5,784.73% and a negative return on equity of 79.74%.

Insiders Place Their Bets

In other news, major shareholder Braden Michael Leonard purchased 13,167 shares of the firm’s stock in a transaction on Monday, August 26th. The shares were bought at an average cost of $3.90 per share, with a total value of $51,351.30. Following the purchase, the insider now directly owns 216,736 shares of the company’s stock, valued at approximately $845,270.40. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have bought 15,033 shares of company stock valued at $58,804 in the last ninety days. Insiders own 46.00% of the company’s stock.

About Talis Biomedical

Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois.